96237-92-2Relevant articles and documents
Structure-Activity Studies Reveal Scope for Optimisation of Ebselen-Type Inhibition of SARS-CoV-2 Main Protease
Brewitz, Lennart,Choudhry, Hani,Malla, Tika R.,Salah, Eidarus,Schofield, Christopher J.,Suits, Timothy F.,Thun-Hohenstein, Siegfried T. D.,Tumber, Anthony
supporting information, (2021/12/30)
The reactive organoselenium compound ebselen is being investigated for treatment of coronavirus disease 2019 (COVID-19) and other diseases. We report structure-activity studies on sulfur analogues of ebselen with the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro), employing turnover and protein-observed mass spectrometry-based assays. The results reveal scope for optimisation of ebselen/ebselen derivative- mediated inhibition of Mpro, particularly with respect to improved selectivity.
